Abstract: The present invention provides intravascular prostheses and methods of production and use. An implantable device for treating a vascular disease or disorder includes an intravascular prosthesis containing an inhibitor of smooth muscle cell proliferation and a growth factor. The device can be coated with a biodegradable drug-eluting polymer that is impregnated with the inhibitor of smooth muscle cell proliferation and the growth factor. The device is useful for treating or preventing a vascular disease or disorder such as restenosis, by simultaneously inhibiting vessel blockage and enhancing recovery of the vessel wall following an intravascular intervention.
Type:
Grant
Filed:
June 2, 2009
Date of Patent:
January 3, 2012
Assignee:
Multi-Gene Vascular Systems Ltd. (“MGVS”)
Abstract: The present invention relates to endothelial and smooth muscle cells genetically altered to express or over-express one or more cell adhesion factors. The invention further relates to cells genetically altered to express or over-express both cell proliferation growth factor(s) and cell adhesion factor(s). In addition, the present invention relates to nucleic acid constructs and nucleic acid construct systems that encode the cell adhesion and cell proliferation growth factors that are used to transfect/transform the cells so that they can express the factors.
Abstract: The present invention relates to compositions and methods for treating and/or preventing ocular disorders, diseases or conditions and compositions and methods for treating or preventing ophthalmic conditions and disorders in a subject in need thereof.
Abstract: The present relates to artificial vascular grafts and for methods for performing hemodialysis with the same. The grafts comprise an inner surface on which cells genetically altered to express or over-express one or more cell adhesion factors, such as fibulin-5, or one or more cell adhesion factors and one or more cell proliferation growth factors, such as VEGF, are seeded and cultured.
Abstract: This invention relates to a method for producing angiogenesis in a tissue of a patient by administering vascular cells genetically altered to over-express an angiogenic proliferation factor and an angiogenic maturation factor to the affected tissue.
Type:
Grant
Filed:
May 2, 2003
Date of Patent:
August 3, 2010
Assignee:
Multi-Gene Vascular Systems Ltd.
Inventors:
Moshe Y. Flugelman, Zoya Gluzman, Meir Preis, Belly Koren, Tzafra Cohen, Adili Tsaba, Anat Weisz
Abstract: The present invention provides intravascular prostheses and methods of production and use. An implantable device for treating a vascular disease or disorder includes an intravascular prosthesis containing an inhibitor of smooth muscle cell proliferation and a growth factor. The device can be coated with a biodegradable drug-eluting polymer that is impregnated with the inhibitor of smooth muscle cell proliferation and the growth factor. The device is useful for treating or preventing a vascular disease or disorder such as restenosis, by simultaneously inhibiting vessel blockage and enhancing recovery of the vessel wall following an intravascular intervention.
Type:
Application
Filed:
June 2, 2009
Publication date:
October 22, 2009
Applicant:
Multi-Gene Vascular Systems LTD. ("MGVS")
Abstract: The present invention provides intravascular prostheses and methods of production and use. An implantable device for treating a vascular disease or disorder includes an intravascular prosthesis containing an inhibitor of smooth muscle cell proliferation and a growth factor. The device can be coated with a biodegradable drug-eluting polymer that is impregnated with the inhibitor of smooth muscle cell proliferation and the growth factor. The device is useful for treating or preventing a vascular disease or disorder such as restenosis, by simultaneously inhibiting vessel blockage and enhancing recovery of the vessel wall following an intravascular intervention.
Abstract: The present invention relates to endothelial and smooth muscle cells genetically altered to express or over-express one or more cell adhesion factors. The invention further relates to cells genetically altered to express or over-express both cell proliferation growth factor(s) and cell adhesion factor(s). In addition, the present invention relates to nucleic acid constructs and nucleic acid construct systems that encode the cell adhesion and cell proliferation growth factors and that are used to transfect/transform the cells so that they can express the factors.
Abstract: The present invention relates to artificial vascular grafts, methods for manufacturing and uses for them. The grafts are coated on their lumen with UP50. The grafts comprise an inner surface on which cells genetically altered to express or over-express one or more cell adhesion factors and one or more cell proliferation factors are seeded and cultured.